3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Lung Neoplasms
2
Colonic Neoplasms
2
Breast Neoplasms
2
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Trastuzumab
594
Paclitaxel
561
Cyclophosphamide
545
Docetaxel
478
Capecitabine
387
Letrozole
350
Fulvestrant
310
Doxorubicin
285
Carboplatin
277
Tamoxifen
257
Anastrozole
219
exemestane
211
Epirubicin
210
Radiotherapy
197
Bevacizumab
189
pertuzumab
175
Gemcitabine
163
Vinorelbine
162
pembrolizumab
161
Lapatinib
161
palbociclib
152
Exercise
132
Fluorouracil
118
Albumin-Bound Paclitaxel
116
eribulin
108
Magnetic Resonance Spectroscopy
108
130-nm albumin-bound paclitaxel
107
Everolimus
103
Taxes
96
Cisplatin
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Breast Neoplasms
×
Isoflurane
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled
NCT00575354
2008-04-21
CSIABTEC
Nanjing Medical University
Phase 4
Completed
500 enrolled